ArticleThrombosis2012
Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms.
Article in Thrombosis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of intravenous aspirin versus oral aspirin in the treatment of acute coronary syndrome: Answering a clinical query by systematic review and meta-analysis of randomized controlled trials.Indian journal of pharmacologyPooled it
- Low-dose ASA therapy does not alter core or skin temperature during hot-dry or warm-humid heat stress (PSU HEAT project).Physiological reports · 2025Trial
- Low dose aspirin as adjuvant treatment for venous leg ulceration: pragmatic, randomised, double blind, placebo controlled trial (Aspirin4VLU).BMJ (Clinical research ed.) · 2017Trial
- Atherosclerotic plaque evolution predicts cerebral ischemic events in patients with intracranial atherosclerosis: a multicentre longitudinal study using high-resolution MRI.European radiology · 2025Article
- Preventing Preeclampsia With Low-Dose Aspirin: A Systematic Review of Efficacy Across Diverse Populations.Cureus · 2025Review
- Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects.Pharmaceutics · 2023Article
- Genetic Association Study and Machine Learning to Investigate Differences in Platelet Reactivity in Patients with Acute Ischemic Stroke Treated with Aspirin.Biomedicines · 2022Article
- Disparate trends of atherosclerotic plaque evolution in stroke patients under 18-month follow-up: a 3D whole-brain magnetic resonance vessel wall imaging study.The neuroradiology journal · 2022Article
- The pharmacological treatment of acute vestibular syndrome.Frontiers in neurology · 2022Review
- Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases.International journal of molecular sciences · 2021Review
- Personalization of Aspirin Therapy Ex Vivo in Patients with Atherosclerosis Using Light Transmission Aggregometry.Diagnostics (Basel, Switzerland) · 2020Article
- Effects of aspirin on the gastrointestinal tract: Pros vs. cons.Oncology letters · 2020Review
- Obesity and Altered Aspirin Pharmacology.Clinical pharmacokinetics · 2018Review
- Standardised tomato extract as an alternative to acetylsalicylic acid in patients with primary hypertension and high cardiovascular risk - a randomised, controlled trial.Archives of medical science : AMS · 2018Article
- Aspirin resistance in coronary heart disease: Current understandings and strategies.Journal of translational internal medicine · 2016Article
- Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions.PloS one · 2015Observational
- Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease.PloS one · 2015Article
- Article
- Aspirin treatment failure: is this a real phenomenon? A review of the aetiology and how to treat it.JRSM short reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main pharmacological aspects of pharmacodynamics (PD) and pharmacokinetics (PK) of aspirin as antiplatelet agent were unravelled between the late sixties and the eighties, and low-dose aspirin given once daily has been shown to be a mainstay in the current treatment and prevention of cardiovascular disorders. Nevertheless, several PD and PK aspects of aspirin in selected clinical conditions have recently emerged and deserve future clinical attention. In 1994, the term "aspirin resistance" was used for the first time, but, until now, no consensus exists on definition, standardized assay, underlying mechanisms, clinical impact, and possible efficacy of alternative therapeutic interventions. At variance with an undefined aspirin-resistant status, in the last 5 years, the concept of variability in response to aspirin due to specific pathophysiological mechanisms and based on PK and/or PD of the drug has emerged. This growing evidence highlights the existence and possible clinical relevance of an interindividual variability of pharmacological aspirin response and calls for new, large studies to test new low-dose aspirin-based regimens which may ameliorate platelet acetylation, reduce variability in drug responsiveness, and improve clinical efficacy on selected populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.